1. Home
  2. RIGL vs PSNYW Comparison

RIGL vs PSNYW Comparison

Compare RIGL & PSNYW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RIGL
  • PSNYW
  • Stock Information
  • Founded
  • RIGL 1996
  • PSNYW 2017
  • Country
  • RIGL United States
  • PSNYW Sweden
  • Employees
  • RIGL N/A
  • PSNYW 2547
  • Industry
  • RIGL Biotechnology: Pharmaceutical Preparations
  • PSNYW Auto Manufacturing
  • Sector
  • RIGL Health Care
  • PSNYW Consumer Discretionary
  • Exchange
  • RIGL Nasdaq
  • PSNYW Nasdaq
  • Market Cap
  • RIGL 335.5M
  • PSNYW 316.6M
  • IPO Year
  • RIGL 2000
  • PSNYW N/A
  • Fundamental
  • Price
  • RIGL $18.98
  • PSNYW $0.17
  • Analyst Decision
  • RIGL Buy
  • PSNYW
  • Analyst Count
  • RIGL 5
  • PSNYW 0
  • Target Price
  • RIGL $36.40
  • PSNYW N/A
  • AVG Volume (30 Days)
  • RIGL 206.5K
  • PSNYW 43.4K
  • Earning Date
  • RIGL 08-05-2025
  • PSNYW 03-06-2025
  • Dividend Yield
  • RIGL N/A
  • PSNYW N/A
  • EPS Growth
  • RIGL N/A
  • PSNYW N/A
  • EPS
  • RIGL 2.08
  • PSNYW N/A
  • Revenue
  • RIGL $203,077,000.00
  • PSNYW $2,034,261,000.00
  • Revenue This Year
  • RIGL $14.41
  • PSNYW N/A
  • Revenue Next Year
  • RIGL $15.97
  • PSNYW $79.49
  • P/E Ratio
  • RIGL $9.41
  • PSNYW N/A
  • Revenue Growth
  • RIGL 70.16
  • PSNYW N/A
  • 52 Week Low
  • RIGL $8.10
  • PSNYW $0.09
  • 52 Week High
  • RIGL $29.82
  • PSNYW $0.61
  • Technical
  • Relative Strength Index (RSI)
  • RIGL 45.79
  • PSNYW 67.00
  • Support Level
  • RIGL $18.24
  • PSNYW $0.15
  • Resistance Level
  • RIGL $19.38
  • PSNYW $0.18
  • Average True Range (ATR)
  • RIGL 0.77
  • PSNYW 0.01
  • MACD
  • RIGL -0.04
  • PSNYW 0.00
  • Stochastic Oscillator
  • RIGL 43.64
  • PSNYW 69.57

About RIGL Rigel Pharmaceuticals Inc.

Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.

About PSNYW Polestar Automotive Holding UK PLC Class C-1 ADS (ADW)

Polestar Automotive Holding UK PLC operates as an electric vehicle manufacturer. It engages in designing products that are engineered to excite consumers and drive change. Polestar defines market standards in design, technology, and sustainability. Polestar was established as a premium electric car brand by Volvo Cars and Geely Holdings. Polestar has produced two electric performance cars, namely Polestar 1 and Polestar 2. Geographically, it derives a majority of revenue from the United Kingdom.

Share on Social Networks: